Prognostic factors associated with time to disease progression
| Factor . | Category . | N . | Patients progressing, n (%) . | P4-150 log rank . | P4-150 Wald χ . | Relative risk . |
|---|---|---|---|---|---|---|
| Initial dose | 400 mg | 59 | 37 (63) | .0020 | .0005 | 2.34 |
| 600 mg | 112 | 36 (32) | ||||
| Age | Less than 60 y | 101 | 46 (46) | .31 | ||
| At least 60 y | 70 | 27 (39) | ||||
| Sex | Male | 87 | 42 (48) | .099 | .076 | 1.53 |
| Female | 84 | 31 (37) | ||||
| Weight | Less than 70 kg | 83 | 37 (46) | .55 | ||
| At least 70 kg | 88 | 36 (41) | ||||
| Hepatomegaly | No | 133 | 54 (41) | .23 | ||
| Yes | 38 | 19 (50) | ||||
| Splenomegaly | No | 72 | 25 (35) | .14 | ||
| Yes | 99 | 48 (48) | ||||
| Hemoglobin | Less than 100 g/L | 82 | 45 (55) | .0017 | .0002 | 2.50 |
| At least 100 g/L | 89 | 28 (31) | ||||
| WBC count | Less than 30 × 109/L | 99 | 43 (43) | .94 | ||
| At least 30 × 109/L | 72 | 30 (42) | ||||
| Platelets | Less than 100 × 109/L | 59 | 29 (49) | .099 | ||
| At least 100 × 109/L | 112 | 44 (39) | ||||
| Basophils in peripheral blood | Less than 20% | 149 | 67 (45) | .12 | ||
| At least 20% | 22 | 6 (27) | ||||
| Blasts in peripheral blood | Less than 15% | 138 | 56 (41) | .23 | ||
| At least 15% | 33 | 17 (52) | ||||
| Blasts in bone marrow4-151 | Less than 15% | 65 | 20 (31) | .092 | ||
| At least 15% | 88 | 41 (47) | ||||
| Other chromosome abnormalities4-151 | No | 100 | 38 (38) | .086 | ||
| Yes | 60 | 30 (50) |
| Factor . | Category . | N . | Patients progressing, n (%) . | P4-150 log rank . | P4-150 Wald χ . | Relative risk . |
|---|---|---|---|---|---|---|
| Initial dose | 400 mg | 59 | 37 (63) | .0020 | .0005 | 2.34 |
| 600 mg | 112 | 36 (32) | ||||
| Age | Less than 60 y | 101 | 46 (46) | .31 | ||
| At least 60 y | 70 | 27 (39) | ||||
| Sex | Male | 87 | 42 (48) | .099 | .076 | 1.53 |
| Female | 84 | 31 (37) | ||||
| Weight | Less than 70 kg | 83 | 37 (46) | .55 | ||
| At least 70 kg | 88 | 36 (41) | ||||
| Hepatomegaly | No | 133 | 54 (41) | .23 | ||
| Yes | 38 | 19 (50) | ||||
| Splenomegaly | No | 72 | 25 (35) | .14 | ||
| Yes | 99 | 48 (48) | ||||
| Hemoglobin | Less than 100 g/L | 82 | 45 (55) | .0017 | .0002 | 2.50 |
| At least 100 g/L | 89 | 28 (31) | ||||
| WBC count | Less than 30 × 109/L | 99 | 43 (43) | .94 | ||
| At least 30 × 109/L | 72 | 30 (42) | ||||
| Platelets | Less than 100 × 109/L | 59 | 29 (49) | .099 | ||
| At least 100 × 109/L | 112 | 44 (39) | ||||
| Basophils in peripheral blood | Less than 20% | 149 | 67 (45) | .12 | ||
| At least 20% | 22 | 6 (27) | ||||
| Blasts in peripheral blood | Less than 15% | 138 | 56 (41) | .23 | ||
| At least 15% | 33 | 17 (52) | ||||
| Blasts in bone marrow4-151 | Less than 15% | 65 | 20 (31) | .092 | ||
| At least 15% | 88 | 41 (47) | ||||
| Other chromosome abnormalities4-151 | No | 100 | 38 (38) | .086 | ||
| Yes | 60 | 30 (50) |
Results are shown for univariate (log-rank) and multivariate analysis (Wald χ). Factors significant atP < .2 in univariate analysis were included in the multivariate model. Factors in the multivariate model were sequentially added in order of greatest significance until the final model included only factors showing an effect with P < .1.
Multivariate analysis limited to patients with available data for all prognostic factors.